A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer

Cancer Discovery

Volumn 7, Issue 6, 2017, Pages 610-619

  Van Geel, Robin M J M ^a   Tabernero, Josep ^b   Elez, Elena ^b   Bendell, Johanna C ^c   Spreafico, Anna ^d   Schuler, Martin ^e   Yoshino, Takayuki ^f   Delord, Jean Pierre ^g   Yamada, Yasuhide ^h   Lolkema, Martijn P ^i,j   Faris, Jason E ^k   Eskens, Ferry A L M ^j   Sharma, Sunil ^l   Yaeger, Rona ^m   Lenz, Heinz Josef ⁿ   Wainberg, Zev A ^o   Avsar, Emin ^p   Chatterjee, Arkendu ^p   Jaeger, Savina ^q   Tan, Eugene ^p   Maharry, Kati ^r   Demuth, Tim ^p   Schellens, Jan H M ^a,s   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j ERASMUS MC CANCER INSTITUTE   (Netherlands)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o UCLA MEDICAL CENTER   (United States)

^p NOVARTIS PHARMA AG   (Switzerland)

^q NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^r ARRAY BIOPHARMA INC   (United States)

^s UTRECHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; B RAF KINASE; CETUXIMAB; ENCORAFENIB; EPIDERMAL GROWTH FACTOR DERIVATIVE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; WNT1 PROTEIN; ANTINEOPLASTIC AGENT; CARBAMIC ACID DERIVATIVE; NVP-BYL719; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTICLE; BACKACHE; BODY WEIGHT DISORDER; CELL PROLIFERATION; CONSTIPATION; COUGHING; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PIGMENTED NEVUS; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAMATES; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THIAZOLES;

EID: 85020402539     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0795     Document Type: Article

References (43)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-64.
3. De Roock W, Biesmans B, De Schutter J, Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diagn Ther 2009; 13: 103-14.
4. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, et al. Prognostic vs. predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild-type status required for anti-EGFR therapy?. Cancer Treat Rev 2010; 36: S56-61.
5. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15: 390-404.
6. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007; 104: 18654-9.
7. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-6.
8. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
9. Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131: 980-6.
10. Zelboraf. Summary of Product Characteristics. [Internet].: F. Hoffmann-La Roche; 2012 [cited May 2015]. Available at: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002409/WC500124317.pdf.
11. Tafinlar. Summary of Product Characteristics [Internet].: GlaxoSmith-Kline; 2013 [cited May 2015]. Available at: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf.
12. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
13. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-67.
14. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
15. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28: 3534.
16. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373: 726-36.
17. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33: 4023-31.
18. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779-89.
19. Caponigro G, Cao ZA, Zhang X, Wang HQ, Fritsch CM, Stuart DD. Efficacy of the RAF/PI3Ka/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600E colorectal tumor models. Cancer Res 2013; 73: 2337.
20. Stuart DD, Li N, Poon DJ, Aardalen K, Kaufman S, Merritt H, et al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Cancer Res 2012; 72: Abstract 3790.
21. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014: 1117-29.
22. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD, et al. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 2012; 72: CT-01.
23. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-94.
24. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-94.
25. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
26. Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 2013; 8: e65995.
27. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-59.
28. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33: 103.
29. Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAFmutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-20.
30. Gomez-Roca CA, Delord J, Robert C, Hidalgo M, von Moos R, Arance A, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, Phase 1 study. Ann Oncol 2014; 25: 535P.
31. Jaka A, Gutierrez-Rivera A, Lopez-Pestana A, Del Alcazar E, Zubizarreta J, Vildosola S, et al. Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity. Actas Dermosifiliogr 2015; 106: 483-92.
32. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
33. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 2010; 464: 427-30.
34. Juric D, Burris H, Schuler M, Schellens J, Berlin J, Seggewiß-Bernhardt R, et al. Phase I study of the PI3Kα inhibitor BYL719, as a single agent in patients with advanced solid tumors (AST). Ann Oncol 2014; 25: 451PD.
35. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
36. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-45.
37. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-23.
38. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 2012; 488: 665-9.
39. Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-53.
40. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-67.
41. Dummer R, Robert C, Nyakas M, McArthur G, Kudchadkar RR, Gomez-Roca C, et al. Initial results from a Phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol 2013; 31: 9028.
42. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420-39.
43. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials 2010; 7: 5-18.